These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31567244)

  • 1. New Drug for Hypoactive Sexual Desire Disorder in Premenopausal Women.
    Aschenbrenner DS
    Am J Nurs; 2019 Oct; 119(10):21. PubMed ID: 31567244
    [No Abstract]   [Full Text] [Related]  

  • 2. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
    Mayer D; Lynch SE
    Ann Pharmacother; 2020 Jul; 54(7):684-690. PubMed ID: 31893927
    [No Abstract]   [Full Text] [Related]  

  • 3. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
    Kingsberg SA; Clayton AH; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Simon JA
    Obstet Gynecol; 2019 Nov; 134(5):899-908. PubMed ID: 31599840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):114-116. PubMed ID: 31381550
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
    Simon JA; Kingsberg SA; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Clayton AH
    Obstet Gynecol; 2019 Nov; 134(5):909-917. PubMed ID: 31599847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
    Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
    J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women.
    Holt H; Tingen J
    Am Fam Physician; 2016 May; 93(10):826-8. PubMed ID: 27175717
    [No Abstract]   [Full Text] [Related]  

  • 8. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
    Clayton AH; Althof SE; Kingsberg S; DeRogatis LR; Kroll R; Goldstein I; Kaminetsky J; Spana C; Lucas J; Jordan R; Portman DJ
    Womens Health (Lond); 2016 Jun; 12(3):325-37. PubMed ID: 27181790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.
    Wessells H; Levine N; Hadley ME; Dorr R; Hruby V
    Int J Impot Res; 2000 Oct; 12 Suppl 4():S74-9. PubMed ID: 11035391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study.
    Simon JA; Derogatis L; Portman D; Brown L; Yuan J; Kissling R
    J Sex Med; 2018 Mar; 15(3):387-395. PubMed ID: 29502984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
    Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
    J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bremelanotide: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2019 Sep; 79(14):1599-1606. PubMed ID: 31429064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
    Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
    J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flibanserin and its discontents.
    Aftab A; Chen C; McBride J
    Arch Womens Ment Health; 2017 Apr; 20(2):243-247. PubMed ID: 27858170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial.
    Vale FBC; Zanolla Dias de Souza K; Rezende CR; Geber S
    Gynecol Endocrinol; 2018 May; 34(5):442-445. PubMed ID: 29172782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
    Koochaki P; Revicki D; Wilson H; Pokrzywinski R; Jordan R; Lucas J; Williams LA; Sadiq A; Krop J
    J Womens Health (Larchmt); 2021 Apr; 30(4):587-595. PubMed ID: 33538638
    [No Abstract]   [Full Text] [Related]  

  • 17. Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
    Kingsberg SA; Clayton AH; Portman D; Krop J; Jordan R; Lucas J; Simon JA
    J Sex Res; 2021; 58(9):1106-1107. PubMed ID: 33835907
    [No Abstract]   [Full Text] [Related]  

  • 18. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.
    Clayton AH; Dennerstein L; Pyke R; Sand M
    Womens Health (Lond); 2010 Sep; 6(5):639-53. PubMed ID: 20887163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flibanserin for female sexual dysfunction.
    Reviriego C
    Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.
    Jaspers L; Feys F; Bramer WM; Franco OH; Leusink P; Laan ET
    JAMA Intern Med; 2016 Apr; 176(4):453-62. PubMed ID: 26927498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.